EpiPen maker Mylan reported a first-quarter profit that edged past expectations, helped by demand for products of Meda, a Swedish company it bought earlier. Fred Katayama reports.
Peoples are using these keywords: Mylan, Mylanfred katayama, profit, 2017 forecast, Epipen, Advair asthma treatment, Us food and drug administrations, Fda, Fred katayama

You might also like this

Speak Your Mind